Rituximab


image_pdfimage_print

Rituximab

This series of graphics describes the different mechanisms of action that have been proposed for this monoclonal drug therapy. The aim of the therapy is to deplete B cells in order to interrupt several key aspects of an ongoing autoimmune response. The graphics explain the possible mechanisms involved.

View associated Case Study – A 7 year old with severe muscle weakness and difficulty walking

Download Rituximab Mode of Action Guide

CD20 induced Apoptosis

 

 

 

 

 

 

 

Classical complement activation

 

 

 

 

 

 

 

C3B Opsonisation and Phagacytosis

 

 

 

 

 

 

 

LgG Opsonisation and Phagocytosis

 

 

 

 

 

 

 

Antibody Dependent cell cytotoxicity by natural killer cells

 
 
 
 
 
 
International Union of Immunological SocietiesUniversity of South AfricaInstitute of Infectious Disease and Molecular MedicineScience Education PrizesElizabeth Glazer Pediatric Aids FoundationAlere